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Tenckhoff tunneled peritoneal catheter placement in palliative treatment of malignant 
ascites: technical results and overall clinical outcome 
 
Abstract 
Purpose: To assess the technical and clinical outcome of percutaneous insertion of tunneled 
peritoneal catheters in the palliative treatment of refractory malignant ascites and to determine 
the safety and feasibility of intraperitoneal administration of cytotoxic drugs through the 
tunneled catheter. 
Materials & methods: Consecutive patients palliatively treated with a tunneled peritoneal 
catheter to drain the malignant ascites were identified. Patients’ medical history, procedural 
and clinical follow-up data, including complications and estimated survival, were reviewed. 
Additionally, a sub analysis of the patients with widespread ovarian cancer and refractory 
ascites treated with or without intraperitoneal administration of cytotoxic drugs were 
analyzed. 
Results: In all 94 patients it was technically feasible to insert the peritoneal drainage catheter 
and to drain a median of 3260 cc (range 100 cc – 8500 cc) of malignant ascitic fluid. Post 
procedural complications included catheter infection (n=2; 2%), fluid leakage around the 
entry site (n=4; 4%), catheter occlusion (n=2; 2%), sleeve formation around the catheter tip 
(n=1; 1%) and accidental loss of the catheter (n=1; 1%). There was no increase in catheter 
infection rate in patients treated with or without intraperitoneal administration of cytotoxic 
drugs. Median overall survival after catheter insertion is 1.7 months. 
Conclusion: Percutaneous insertion of a tunneled Tenckhoff catheter for the palliative 
drainage of malignant ascites and intraperitoneal infusion of cytotoxic drugs is feasible and 
associated with a very low complication rate, including catheter infection. These tunneled 
  
peritoneal lines are beneficial for symptomatic palliative treatment of refractory ascites and allow 
safe intraperitoneal chemotherapy. 
Key words: peritoneal catheter; malignant ascites;  palliation 
  
  
Introduction 
Malignant ascites is a manifestation of terminal metastatic disease with a life expectancy 
ranging from 1 to 4 months; the ascitic fluid production is usually associated with peritoneal 
tumours, lymphangitic carcinomatosis, lymphatic obstruction, encasement of the portal vein 
by a tumour causing prehepatic portal hypertension, or a combination of these 
pathophysiological mechanisms [1-3]. Clinically, these patients suffer from abdominal 
distension, early satiety, shortness of breath, fatigue or gastrointestinal symptoms such as 
nausea and vomiting. Medical treatment, including diuretics, have little or no effect on 
malignant fluid accumulation and the standard treatment for these patients was repeated 
paracentesis, despite the risks of infection, haemorrhage or bowel wall injury and the need for 
frequent trips to the hospital [4]. In the past decade, alternative drainage options intended to 
avoid repetitive punctures, have been tested and used. These drainage techniques include 
internal drainage like peritoneo-venous (11), peritoneo-gastric (16) and peritoneo-cystic (17) 
shunting and external drainage techniques requiring the placement of an indwelling, tunneled 
peritoneal drainage or port-catheter [2, 3, 5-11]. An important disadvantage of external 
drainage is albumin loss, which may need to be considered in deciding between external 
drainage and internal shunts. Most of the experience with indwelling drainage catheters has 
described with the PleurX catheter; this monocuffed catheter was initially designed for 
drainage of malignant pleural effusions but it can also be used for drainage of malignant 
peritoneal fluid [3, 6-8]. Additionally, if this type of indwelling tunneled catheter is used, it is 
recommended to use vacuum bottles for adequate drainage.  
In this study we retrospectively analysed the technical feasibility and safety of the insertion of 
a Tenckhoff peritoneal tunnelled catheter. Additionally, the overall clinical outcomes in this 
patient population were analysed and finally we evaluated the feasibility and safety of 
  
intraperitoneal chemotherapy delivery through the Tenckhoff catheter in patients with 
widespread ovarian cancer and refractory ascites using catumaxomab. 
 
  
  
Materials and Methods 
Patients and study design: 
A retrospective analysis was carried out on consecutive patients in whom a Tenckhoff 
tunnelled peritoneal catheter was inserted percutaneously for the management of refractory 
malignant ascites in the authors’ institution between March 2006 and January 2013. The 
inclusion criteria for catheter placement were symptomatic, malignant ascites refractory to 
conservative and medical management in patients with widespread metastatic disease; 
haemostatic parameters allowing small skin incisions and subcutaneous tunnelling; absence of 
compartmentalization of the malignant ascitic fluid. Active infection is considered as an 
exclusion criterion for catheter insertion. Refractory malignant ascites is defined as ascites in 
patients with widespread metastatic disease in whom the ascites cannot be mobilized by 
conservative or medical therapies. Patients’ history, procedural and post-procedural data were 
documented based on the patients’ hospital electronic medical records and after telephone 
calls with the patients’ general practitioners. 
The patients gave informed consent before the start of the interventional procedure and 
institutional review board approval was obtained for this retrospective study analysis. 
 
Interventional procedure of Tenckhoff catheter placement:  
Patients were referred to the interventional radiology department after discussion between the 
attending interventional radiologist and medical or surgical oncologist. Patient preparation 
included a bedside ultrasound for evaluation of the amount of ascites and more specifically 
for evaluation of a window of ascitic fluid at the intraperitoneal puncture site. The preferred 
intraperitoneal puncture site was near the midline, inferior and to the right of the umbilicus; if 
no ascitic fluid window was identified in that area, a left-sided infra-umbilical puncture site 
was prepared with a tunnel area to the left flank. Laboratory analysis included acceptable 
  
haematological parameters for tunneled catheter insertion, including a platelet count of at least 
50,000/L, a haemoglobin level > 8 g/dL and an International Normalized Ratio (INR) of less 
than 1.5. Tenckhoff tunneled peritoneal drainage catheter insertion was performed under 
sterile conditions in the interventional radiology suite.  
After standard surgical preparation, local anaesthesia of the puncture site and the 
subcutaneous tunnel area was administered with 30 mL of lidocaine hydrochloride (Linisol 
2%, B. Braun, Diegem, Belgium). No other sedation or prophylactic antibiotic medication 
was administered; a 2 cm skin incision was made near the midline, inferior and to the right (or 
left) of the umbilicus and ultrasound-guided puncture of the malignant ascitic fluid was 
carried out using an 18 gauge (G) sheathed needle (Surflo I.V. Catheter, Terumo Europe, 
Leuven, Belgium) (Fig. 1a). A 0.035 inch hydrophilic guide wire (HydroSteer, St-Jude 
Medical, St-Paul, MN, USA) was introduced into the peritoneal cavity using a 0.035 inch 4 
French (F) Cobra catheter (Slip-cath, Cook Medical, Bjaeverskov, Denmark) positioned in the 
pelvis (Fig. 1b). This was then exchanged for a 0.035 inch stiff guide wire (Amplatz, Cook 
Medical, Bjaeverskov, Denmark) (Fig. 1c). Over the stiff guide wire the puncture tract was 
dilated using a 8F dilator (Cook Medical, Bjaeverskov, Denmark) and finally a 15F peel-away 
introducer (PTFE-peel-Apart, BARD Benelux, Olen, Belgium) was inserted (Fig. 1d). The 
Tenckhoff peritoneal drainage catheter (Argyle peritoneal dialysis catheter, Covidien, 
Mansfield, MA, USA) with the Cobra catheter inside was introduced over the stiff guide wire 
into the peritoneal cavity and positioned in a curved position in the lower pelvic region (Fig. 
1e). The Tenckhoff catheter is made of translucent silicone rubber tubing containing a radio-
opaque stripe. The total length of the 15F catheter is 47 cm and the inner diameter is 2.6 mm. 
The intraperitoneal part of the catheter contains small fenestrations over a length of 15 cm 
(Fig. 2). The cuffed end of the Tenckhoff catheter is tunnelled to the right (or left) flank using 
a metallic tunnelling device (Argyle Faller Tunneling device, Covidien, Mansfield, MA, 
  
USA)  and exteriorized 7 cm lateral to the peritoneal entry site. Finally, the small cutaneous 
incisions are sutured and the external part of the tunnelled catheter is connected to a drainage 
bag (3L Empty Bag System II, Baxter Healthcare, Zurich, Switzerland) using a sterile 
connecting device (Connection Shield System II with Povidone-Iodine Solution, Baxter 
Healthcare, Zurich, Switzerland) to begin drainage.  
The intraperitoneal chemotherapy infusion technique was performed using a catumaxomab-
based regimen as described by Baumann et al. [12].  Briefly, catumaxomab (Removab®, 
Neovii Biotech, Waltham, MA, USA)  10 microgram (µg), 20 µg, 50 µg and 150 µg in 
250 mL of 0.9 % NaCl physiologic solution was injected intraperitoneally through the 
Tenckhoff catheter, respectively at day 1, 4, 8 and 11 of the treatment. 
Patients were followed up until the end of the study (March 2013) or the patient’s death. 
 
 
Statistical analysis: 
Overall survival probabilities are estimated by the Kaplan-Meier method. The Wilcoxon test 
is used for testing survival differences between ovarian cancer patients with or without 
intraperitoneal chemotherapy treatment (IPCT). The prognostic value of primary pathology 
for survival is analysed using Cox proportional hazards models. Fisher’s exact test is used for 
the association between intraperitoneal chemotherapy treatment and catheter infection.  
All tests are two-sided. A 5% significance level is assumed for all tests. All analyses have 
been carried out using SAS software, version 9.3 of the SAS System for Windows (SAS 
Institute Inc., Cary, NC, USA). 
  
  
Results 
Patient demographics: 
In 94 patients (27 men; 28.7% and 67 women; 71.3%) with a mean age of 60.1 years (median 
59.4 years; standard deviation 12.4 years) a tunnelled peritoneal Tenckhoff catheter was 
inserted for drainage of malignant ascites. Malignant ascites was associated with different 
types of metastatic cancer disease as summarized in Table I. The category ‘rest’ included lung 
carcinoma (n=2), multiple myeloma (n=2) and myxoid liposarcoma (n=1). 
The number of paracenteses prior to Tenckhoff catheter insertion is indicated in Table II; 
overall, patients underwent a mean of 3.4 paracenteses (median: 2.0; standard deviation: 5.6; 
range: 0 – 44 paracenteses). In 15 out of 94 patients (16%) intraperitoneal chemotherapy 
treatment (IPCT) with catumaxomab was given; these 15 patients suffered from widespread 
metastatic ovarian cancer associated with refractory malignant ascites. 
 
Technical outcome: 
In all patients (100%), the Tenckhoff tunnelled peritoneal drainage catheter was successfully 
inserted; in 90 patients (96%), the Tenckhoff catheter was tunnelled subcutaneously into the 
right flank, in the remaining 4 patients (4%) the peritoneal access was made in the left para 
and infraumbilical region and the catheter was tunnelled into the left flank. Once the 
Tenckhoff catheter was in place, a median of 3,260 cc (range 100 cc – 8,500 cc) of malignant 
ascitic fluid was drained.  
 
Clinical outcome: 
Clinical follow-up was available for 90 patients; 4 patients (4.2%) were lost to follow-up.  
Two patients (2.1%) presented with a clinical suspicion of catheter infection, including fever, 
painful cutaneous and subcutaneous tunnel infection, but without clear signs of peritonitis, 36 
  
& 40 days respectively after initial catheter placement. One of these two patients was also 
treated with intraperitoneal chemotherapy infusions. Other minor complications included 
ascitic fluid leakage around the entry point of the catheter in the right flank (n=4; 4%), 
catheter occlusion (n=2; 2%) and sleeve formation around the tip of the catheter resulting in 
insufficient drainage (n=1; 1%). Management of these complications included extra skin 
sutures around the catheter entry point (n=4), catheter removal (n=1) or catheter flushing 
(n=2) respectively. 
In another three patients (3%), initially presenting with malignant ascites related to breast 
carcinoma (n=1), endometrial carcinoma (n=1) and ovarian carcinoma (n=1), the Tenckhoff 
catheter was removed after 111, 134 and 39 days respectively, owing to regression of ascitic 
fluid production. Another patient accidentally lost the catheter 11 days after initial placement. 
Five out of 90 patients (5.3%) were still alive at the end of the study (March 2013); the 
remaining 85 patients (90.4%) died before March 2013. The time interval until end of follow-
up or the patient’s death was a mean of 3.41 months (median 1.7 months; standard deviation: 
4.73; min: 0.03, max 25.7 months). 
Kaplan-Meier estimates for overall survival after Tenckhoff insertion is summarized in Figure 
3 and Table III, showing an estimated survival at 3 and 6 months of nearly 30% and 18% 
respectively. Further, a more detailed analysis of survival after Tenckhoff catheter insertion is 
made based on the underlying type of cancer. We analysed five categories of underlying 
aetiologies: gynaecological cancers (n=40) including ovarian and endometrial cancers; 
hepatobiliary cancers (n=22) including pancreatic cancer, cholangiocarcinoma and 
hepatocellular carcinoma; gastrointestinal cancers (n=11) including colorectal cancer, gastric 
cancer and neuroendocrine tumours; breast carcinoma (n=11) and rest (n=5) including lung 
carcinoma (n=2), multiple myeloma (n=2) and myxoid liposarcoma (n=1); the survival of 
these different groups is summarized in Fig. 4. Analysis suggests a difference in risk for early 
  
death after Tenckhoff catheter insertion according to the underlying cancer: patients with 
widespread gastrointestinal cancers and refractory malignant ascites have a higher risk for 
early death compared to the reference group of patients with widespread metastatic 
gynaecological cancers (Fig. 6). 
Overall survival after clinical diagnosis of malignant ascites demonstrates a 3 and 6 month 
estimated survival of 82.0% and 63.9% respectively, as shown in Table IV and Fig 5.). An 
analysis of the potential outcome differences between the five categories of  cancer mentioned 
above was carried out and summarized in Table V and Fig. 6. The risk analysis for early death 
after clinical diagnosis of malignant ascites also demonstrates a significant difference in 
survival for patients with malignant gynaecological cancer compared to patients with 
gastrointestinal cancers (p= 0.007). 
Tunnelled Tenckhoff catheters were inserted in a total of 38 patients presenting with 
metastatic ovarian cancer and malignant ascites. In 23 of these patients the Tenckhoff catheter 
was inserted solely for repeated drainage purposes. In the remaining 15 patients the Tenckhoff 
catheter was inserted for the purpose of drainage of malignant ascites and for the purpose of 
intraperitoneal infusion of a catumaxomab-based solution. Overall survival of the two sub-
groups of patients (Table VI and Fig. 7) revealed better survival in the group with 
intraperitoneal infusion of catumaxomab (p = 0.02).  
 
  
  
Discussion 
This study demonstrates a very high technical success rate (100%) for tunnelled, peritoneal 
Tenckhoff catheter insertion in patients suffering from refractory malignant ascites, which is 
in line with experiences in other centres using the same [2, 13] or other types of tunnelled 
peritoneal catheters such as the PleurX-catheter [3, 5-8] or Medcomp catheter [14]. 
Furthermore, subcutaneous insertion of port catheters has a 100% success rate [9, 10], 
although there are only a few reports covering a small number of included patients. The major 
difference between the PleurX catheter and the Tenckhoff or Medcomp catheter is the number 
of cuffs: the PleurX catheter has one cuff whereas the other two have two cuffs; the number of 
infection events with these different types of tunnelled catheters does not, however, seem to 
be different: we encountered two patients (2%) with clinical signs of infection which is almost 
identical to the series with the PleurX catheter [6, 8]. 
The technique of tunnelled catheter insertion is essentially the same for the different types of 
peritoneal tunnelled catheters: percutaneous access to the peritoneal cavity is gained under 
ultrasound guidance using Seldinger technique and insertion of the catheter through a peel-
away sheath can be performed blindly or under fluoroscopic guidance. When using these 
techniques, however, the position of the tip of the tunnelled catheter is not always predictable. 
Instead, we used a catheter-based technique (Cobra catheter and hydrophilic guide wire) to 
position the tip and the fenestrated area of the Tenckhoff catheter in the dependent portion of 
the peritoneal cavity (lower pelvic region) which might result in better drainage of the ascitic 
fluid later on, especially when the patient is in a sitting or supine position, although catheter 
tip migration after insertion is still possible especially in case of recurrent ascitic fluid 
accumulation associated with bowel and body movements in general.  
Other post-procedural complications apart from infection are almost always minor 
complications and may include fluid leakage around the catheter entry point, catheter 
  
occlusion or accidental loss despite the presence of two cuffs. This very low rate of serious 
complications may suggest earlier referral for Tenckhoff catheter placement for the palliative 
drainage of malignant ascites resulting in patients’ improved quality of life.  
Importantly, this study also suggests the usefulness of the Tenckhoff catheter for 
intraperitoneal administration of chemotherapeutic agents such as catumaxomab without a 
significant increase in adverse, infectious events, although the number of patients treated with 
intraperitoneal chemotherapy infusion was small (n=15). 
The life expectancy of patients with refractory malignant ascites is very poor, with a range 
from 1 to 4 months, which is in line with the overall results of this study, showing a median 
overall survival of 1.7 months. This short life expectancy mainly depends on the natural 
history of the underlying widespread malignancy and subsequently patients with a longer life 
expectancy associated with refractory malignant ascites, such as patients with gynaecological 
tumours, may also benefit from the tunnelled Tenckhoff catheter for a longer period compared 
to patients with more aggressive tumours such as gastrointestinal malignancies.  
Finally, a sub-analysis of patients with refractory ascites and widespread malignant ovarian 
tumours reveals improved survival if catumaxomab is administered intraperitoneally 
(p=0.02). This conclusion should be interpreted with caution, however, because this is a 
retrospective, single-centre, non-randomized analysis including a small number of patients. 
Additionally, a multi-centre, randomized open-label phase IIa study was only able to 
demonstrate a slightly better therapeutic index in a high-dose catumaxomab regimen as 
compared to a low-dose regimen [12] and other researchers found a non-significant survival 
benefit (110 days versus 81 days) if intraperitoneal administration of catumaxomab took place 
in patients with recurrent ovarian cancer [15]. 
In conclusion, this study demonstrates that percutaneous image-guided insertion of a 
tunnelled Tenckhoff catheter in the peritoneal cavity is safe and effective for drainage of 
  
refractory malignant ascites, with a very low complication rate including catheter infection. 
The catheter is also an efficient and safe tool for intraperitoneal administration of cytotoxic 
drugs with no increase in peritonitis or other infectious adverse events. Finally, owing to the 
natural course of the underlying malignant tumor, patients with widespread metastatic 
gynaecological cancers and refractory ascites may benefit for a longer period from this 
interventional procedure than patients with other cancers and associated malignant ascites. 
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Table I: Type of primary cancer 
Primary malignant disease Statistic All 
Gynaecological  cancer n/N (%) 41/94 (43.6%) 
Ovarian cancer n/N 38/94  
Endometrial cancer n/N 3/94 
Hepatobiliary cancer n/N (%) 24/94 (25.5%) 
Pancreatic cancer n/N 11/94 
Cholangiocarcinoma n/N 12/94 
Hepatocellular carcinoma n/N 1/94 
Gastrointestinal cancer n/N (%) 11/94 (11.7%) 
Colorectal cancer n/N 6/94 
Gastric cancer  n/N 3/94 
Small bowel neuroendocrine cancer n/N 2/94 
Breast cancer n/N (%) 13/94 (13.8%) 
Rest n/N (%) 5/94 (5.3%) 
 
  
  
Table II: Paracenteses prior to Tenckhoff catheter placement 
Number of paracenteses Statistic All 
0 n/N (%) 19/94 (20.2%) 
1 n/N (%) 20/94 (21.3%) 
2 n/N (%) 16/94 (17.0%) 
3 n/N (%) 15/94 (16.0%) 
4 or > 4  n/N (%) 24/94 (25.5%)  
 
  
  
Table III: Kaplan-Meier estimates for overall survival since Tenckhoff insertion at specific 
follow-up times (+95% confidence interval) 
Months since Tenckhoff insertion % Survival Lower limit Upper limit 
3 30.0 20.9 39.6 
6 18.0 10.8 26.8 
12 7.7 3.2 14.5 
18 2.6 0.3 9.9 
24 2.6 0.3 9.9 
 
  
  
Table IV: Kaplan-Meier estimates for overall survival since clinical diagnosis of ascites at 
specific follow-up times (+ 95% confidence interval). 
Months since clinical diagnosis of ascites % Survival Lower limit Upper limit 
3 82.2% 72.6% 88.7% 
6 63.2% 53.3% 72.2 % 
12 44.7 %  34.1%  54.7% 
18 30.6% 21.2% 40.4% 
24 24.7% 16.2% 34.1% 
 
  
  
Table V: Analysis of overall survival since clinical diagnosis of malignant ascites for 
different groups of cancers 
 
 Hazard ratio Lower limit Upper limit P-value 
Gynaecological cancers 
(reference) 
- - - 0.06 
Hepatobiliary cancers 1.17 0.68 2.02 0.575 
Gastrointestinal cancers 2.58 1.30 5.13 0.007 
Breast cancer 1.42 0.73 2.74 0.299 
Rest 0.71 0.25 1.99 0.511 
 
  
  
Table VI: Survival analysis in patients with metastatic ovarian cancer and malignant ascites 
treated with or without intraperitoneal infusion of catumaxomab after Tenckhoff catheter 
insertion.  
IPCT 
Median survival 
in months 
95% confidence interval 
Lower limit Upper limit 
With IPCT 3.22 1.61 6.58 
Without IPCT 1.61 0.69 2.40 
 
 
IPCT: intraperitoneal chemotherapy treatment  
 
  
  
Figure legends 
Figure 1a: Ultrasound-guided puncture of the ascitic fluid. The tip of the puncture needle 
(white arrow) is located within the fluid, far from intestinal or other abdominal structures.  
Figure 1b: Using a 4F Cobra catheter (black arrow), the hydrophilic guide wire (arrowheads) 
is navigated to the lower portion of the pelvis. 
Figure 1c: The hydrophilic guide wire is exchanged for a stiff Amplatz wire (arrowheads) on 
the Cobra catheter (arrow). 
Figure 1d: The 15F peel-away sheath (white arrows) is introduced into the peritoneal cavity 
over the stiff Amplatz wire (arrowheads) 
Figure 1e: The Tenckhoff catheter (white arrows) is introduced through the 15F peel-away 
sheath into the peritoneal cavity. 
Figure 2: Schematic drawing of the Tenckhoff catheter: the intraperitoneal portion contains 
small fenestrations over a length of 15 cm. Two cuffs with a length of 1 cm are positioned in 
the subcutaneous tissues.  
Figure 3: Overall survival after Tenckhoff catheter insertion with 95% confidence limits.  
Figure 4: Overall estimated survival for different cancer types after Tenckhoff catheter 
insertion. 
Figure 5: Overall estimated survival since clinical diagnosis of malignant ascites with 95% 
confidence limits.  
Figure 6: Overall estimated survival for different types of cancer since clinical diagnosis of 
malignant ascites. 
Figure 7: Overall estimated survival in patients with metastatic ovarian cancer associated 
with malignant ascites is better if intraperitoneal infusion of catumaxomab through the 
Tenckhoff catheter is carried out (p = 0.02).  
 
